Home/Pipeline/PER303

PER303

Phenylketonuria (PKU)

PreclinicalActive

Key Facts

Indication

Phenylketonuria (PKU)

Phase

Preclinical

Status

Active

Company

Perseo Pharma

About Perseo Pharma

Perseo Pharma is a Swiss biotech developing next-generation enzyme replacement therapies using its proprietary nano-shield platform. The company's technology encapsulates enzymes in silica-based nanoparticles with muco-adhesive coatings, enhancing intestinal residence time and activity while remaining non-systemic. Its pipeline targets digestive enzyme deficiencies like EPI and rare metabolic disorders, with a strategic R&D collaboration with Nestlé Health Science providing validation and resources. Founded in 2019, the company is privately held and currently in the preclinical stage.

View full company profile

Therapeutic Areas

Metabolic Diseases Digestive Diseases Rare Diseases

Other Phenylketonuria (PKU) Drugs

Drug	Company	Phase	Status
SYNB1934	Synlogic	Phase 3	Completed; Did Not Meet Primary Endpoint
PKU Treatment	Cycle Pharmaceuticals	Commercial	Active
NB-20X	Nerai Biosciences	Pre-clinical	Active
NGGT002	NGGT	Phase 1/2 (inferred)	Active
SOM1311	SOM Biotech	Preclinical	Active
Repinatrabit	Otsuka	Open-Label Extension	Active
Engineered Native Bacteria Platform	Endure Biotherapeutics	Pre-clinical	Active
JNT-517	JCR Pharmaceuticals	Phase 1	Active
PALYNZIQ (pegvaliase-pqpz)	BioMarin Pharmaceutical	Approved/Marketed	Active (Label expansion)
PTC923 (sepiapterin)	PTC Therapeutics	Phase 3	Active